Healthcare IT News June 29, 2021
Sophie Porter

The test uses machine learning to identify cancers including ovarian and some blood cancers before clinical signs emerge.

NHS England will pilot a blood test that can detect more than 50 types of cancer before clinical signs or symptoms emerge. This includes ovarian, pancreatic, oesophageal, bowel and lung cancers.

Developed by US-based medtech company GRAIL, the Galleri test uses a machine learning algorithm to examine cell-free DNA (cfDNA) that leaks from tumours into the bloodstream. It detects chemical changes, known as methylation patterns, with a false positive rate of only 0.5%.

Initial studies used patients whose cancer had already been diagnosed through other means and correctly identified cancers in over 50% of cases and correctly located the tissues affected in...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: AI (Artificial Intelligence), Biotechnology, Patient / Consumer, Pharma / Biotech, Provider, Technology
Mastering prompt engineering to elevate AI in clinical practice
AI-Guidance Boosts Arrhythmia Ablation Success in Persistent Cases
HealthTech Acquirers Key Priorities Mid 2024
How Technology is Changing Alzheimer’s and Dementia Testing
AI on the Agenda at 2024 ATS, Says Conference Chair | 2024 ATS

Share This Article